| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Glyoxalase I inhibitor 5 targets Glyoxalase I (Glo-I), a key enzyme in the glyoxalase system. Glo-I catalyzes the conversion of methylglyoxal and glutathione to S-D-lactoylglutathione. Inhibiting Glo-I leads to the accumulation of toxic methylglyoxal.
|
|---|---|
| ln Vitro |
In vitro enzyme assays confirm that Glyoxalase I inhibitor 5 has an IC50 of 1.28 microM against Glo-I. By inhibiting this enzyme, the compound disrupts the detoxification of methylglyoxal, a byproduct of glycolysis that is elevated in cancer cells.
|
| ln Vivo |
Dedicated in vivo efficacy studies for inhibitor 5 are not extensively documented in standard profiles. As a Glo-I inhibitor, it is hypothesized to induce selective cytotoxicity in cancer cells due to their higher metabolic rate and reliance on the glyoxalase system.
|
| Enzyme Assay |
Recombinant human Glyoxalase I enzyme is incubated with its substrate, methylglyoxal (MG), and reduced glutathione (GSH). The formation of the product S-D-lactoylglutathione is measured spectrophotometrically at 240 nm in the presence of varying concentrations of Glyoxalase I inhibitor 5.
|
| Cell Assay |
Cancer cell lines (e.g., HeLa, MCF-7, A549) are cultured and treated with inhibitor 5. Cell viability is assessed via MTT assay after 48-72 hours. Levels of methylglyoxal and advanced glycation end-products (AGEs) in cell lysates can be measured to confirm target engagement.
|
| Animal Protocol |
In vivo protocols would typically involve establishing tumor xenografts in immunodeficient mice. Mice would receive intraperitoneal injections of Glyoxalase I inhibitor 5 daily. Tumor growth inhibition and intratumoral methylglyoxal levels would be assessed.
|
| ADME/Pharmacokinetics |
Detailed PK parameters for Glyoxalase I inhibitor 5 are not extensively documented. As a small molecule with an IC50 in the low micromolar range, its physicochemical properties would need to be optimized for in vivo applications. Comprehensive ADME data is not reported.
|
| Toxicity/Toxicokinetics |
Toxicological data for inhibitor 5 is not available in standard profiles. As an anticancer research compound, comprehensive acute and sub-chronic toxicity studies have not been reported. Standard lab safety precautions apply.
|
| References | |
| Additional Infomation |
Glyoxalase I inhibitor 5 is part of a series of compounds targeting methylglyoxal metabolism. Elevated methylglyoxal levels are a hallmark of many cancers, making Glo-I an attractive target for cancer therapy. The compound is for research use only.
|
| Molecular Formula |
C16H14N4O3S
|
|---|---|
| Molecular Weight |
342.372361660004
|
| Exact Mass |
342.078
|
| CAS # |
2455508-17-3
|
| PubChem CID |
162661421
|
| Appearance |
Brown to orange solid powder
|
| LogP |
2.5
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
24
|
| Complexity |
562
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=C(C=C(C=C1)N=NC2=C3C=CC=NC3=C(C=C2)O)S(=O)(=O)N
|
| InChi Key |
HZHXXZUPMORJKH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H14N4O3S/c1-10-4-5-11(9-15(10)24(17,22)23)19-20-13-6-7-14(21)16-12(13)3-2-8-18-16/h2-9,21H,1H3,(H2,17,22,23)
|
| Chemical Name |
5-[(8-hydroxyquinolin-5-yl)diazenyl]-2-methylbenzenesulfonamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~292.1 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (7.30 mM) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution; with ultrasonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (7.30 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9208 mL | 14.6041 mL | 29.2082 mL | |
| 5 mM | 0.5842 mL | 2.9208 mL | 5.8416 mL | |
| 10 mM | 0.2921 mL | 1.4604 mL | 2.9208 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
